Annexon Inc. Stock News

Investors need to pay close attention to Annexon (ANNX) stock based on the movements in the options market lately.

BRISBANE, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, announced safety and dose-response data from its Phase 1 clinical trial of ANX009, the companys subcutaneously administered product candidate that is designed to block the activity of C1q and the entire classical complement pathway. In addition, Annexon reported preclinical data supporting the role of the complement pathway in warm autoimmune hemolytic anemia (wAIHA). The data were presented during two poster sessions at the 63 rd American Society of Hematology (ASH) Annual Meeting & Exposition.

Goldman Sachs Group Inc. lessened its holdings in shares of Annexon, Inc. (NASDAQ:ANNX) by 83.3% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 22,293 shares of the companys stock after selling 110,896 shares during the quarter. Goldman Sachs Group Inc. owned 0.06% of []

HC Wainwright started coverage on shares of Annexon (NASDAQ:ANNX) in a research report sent to investors on Tuesday morning, Price Targets.com reports. The brokerage issued a buy rating and a $40.00 target price on the stock. Other analysts have also issued reports about the stock. Zacks Investment Research lowered shares of Annexon from a hold []

The shares of Annexon Inc (NASDAQ: ANNX) have received a $40 price target from H.C. Wainwright.

– Dr. Ted Yednock's appointment enhances Annexon's commitment to scientific innovation and pursuit of future programs –

CAMBRIDGE, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patient

CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patient

– Recently expanded Autoimmune franchise with advancement of third clinical candidate, ANX009, and strategically expanded into additional autoantibody-driven diseases –

Advancing subcutaneous ANX009 candidate into Phase 1b program in Lupus Nephritis

SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- Today,  Annexon, Inc.  (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therap

Annexon (ANNX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

SOUTH SAN FRANCISCO, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Today Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies fo

Annexon Inc (NASDAQ: ANNX) has commenced patient dosing in its Phase 2 ARCHER study evaluating ANX007 to treat Geographic Atrophy (GA). GA, also known as atrophic age-related macular degeneratio